The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Mar. 12, 2021
Applicant:

Fate Therapeutics, Inc., San Diego, CA (US);

Inventors:

Bahram Valamehr, San Diego, CA (US);

Raedun Clarke, San Diego, CA (US);

Ryan Bjordahl, San Diego, CA (US);

Assignee:

FATE THERAPEUTICS, INC., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0789 (2010.01); A61K 35/28 (2015.01); A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); G01N 33/50 (2006.01); A61K 35/545 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0647 (2013.01); A61K 35/28 (2013.01); A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); G01N 33/5073 (2013.01); A61K 35/545 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/14 (2013.01); C12N 2501/145 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2311 (2013.01); C12N 2501/235 (2013.01); C12N 2501/415 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01); C12N 2533/90 (2013.01); Y02A 50/30 (2018.01);
Abstract

The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.


Find Patent Forward Citations

Loading…